key: cord-0986512-x4f4csfj
authors: Perveen, Sumera; Yazdi, Aliakbar Khalili; Devkota, Kanchan; Li, Fengling; Ghiabi, Pegah; Hajian, Taraneh; Loppnau, Peter; Bolotokova, Albina; Vedadi, Masoud
title: A high throughput RNA displacement assay for screening SARS-CoV-2 nsp10-nsp16 complex towards developing therapeutics for COVID-19
date: 2020-10-15
journal: bioRxiv
DOI: 10.1101/2020.10.14.340034
sha: 162b304bc4f3f2d8649d70867ef2e342714b9277
doc_id: 986512
cord_uid: x4f4csfj

SARS-CoV-2, the coronavirus that causes COVID-19, evades the human immune system by capping its RNA. This process protects the viral RNA and is essential for its replication. Multiple viral proteins are involved in this RNA capping process including the nonstructural protein 16 (nsp16) which is an S-adenosyl-L-methionine (SAM)-dependent 2’-O-methyltransferase. Nsp16 is significantly active when in complex with another nonstructural protein, nsp10, which plays a key role in its stability and activity. Here we report the development of a fluorescence polarization (FP)-based RNA displacement assay for nsp10-nsp16 complex in 384-well format with a Z′-Factor of 0.6, suitable for high throughput screening. In this process, we purified the nsp10-nsp16 complex to higher than 95% purity and confirmed its binding to the methyl donor SAM, product of the reaction, SAH, and a common methyltransferase inhibitor, sinefungin using Isothermal Titration Calorimetry (ITC). The assay was further validated by screening a library of 1124 drug-like compounds. This assay provides a cost-effective high throughput method for screening nsp10-nsp16 complex for RNA-competitive inhibitors towards developing COVID-19 therapeutics.

segmented positive-sense RNA viruses which have the largest genome among RNA viruses 9, 10 .

Their genomes contain six major open reading frames (ORFs) and various number of accessory genes. They encode 16 nonstructural proteins (nsps) that play essential roles in RNA replication and processing of sub genomic RNA. [11] [12] [13] [14] SARS-CoV-2 replication involves RNA synthesis, proofreading and capping. 15 Coronavirus mRNAs are protected at their 5′ ends by a cap structure consisting of an N7-methylated guanine linked to the first transcribed nucleotide by a 5′-5′ triphosphate bond and 2'-O-methylation (N7-meGpppN-2′-O-me; Fig. 1 ). 16 The RNA capping is essential for stability of viral mRNA and evading the host immune system. Uncapped RNA molecules are identified as 'foreign' by host innate immune response and undergo degradation. 17, 18 Therefore, proteins catalyzing RNAcapping are attractive targets for antiviral drug development. Nsps involved in viral mRNA capping include nsp10 (cofactor for nsp14 and nsp16), 19 nsp13 (RNA 5'-triphosphatase, helicase), 20 nsp14 (guanine-N7 methyltransferase), 21 and nsp16 (2'-O-methyltransferase). 18, 22, 23 The capping process begins with the removal of the 5'γ-phosphate of the newly synthesized RNA chains (pppN-RNA) by nsp13. 20 Then a guanylyltransferase (GTase) leads to the formation of GpppN-RNA, by transferring a Guanosine monophosphate (GMP) molecule to the 5'-diphosphate of the RNA chains (ppN-RNA). Nsp14 methylates the cap structure at the N7 position of the guanosine, resulting in the formation of cap-0 (N7-meGpppN-RNA). 21 Ultimately, the nsp10-nsp16 complex catalyzes the addition of a methyl group on the ribose 2′-O position of the first transcribed nucleotide of the cap-0 (N7-meGpppN-RNA) to form a cap-1 (N7-meGpppNme-RNA) (Fig. 1) . 23, 24 In vitro, methyltransferase activity has been reported for nsp10-nsp16 complexes from feline CoV (FCoV), 25 SARS-CoV, 23 and MERS-CoV, 26 and the binding of various RNAs to MERS-CoV have been assessed and used to rank-order substrates. 26 Nsp10 acts as an allosteric activator of nsp16 and is essential for its stability and activity, 18, 27 increasing its binding affinity for RNA substrate and SAM in both SARS and MERS-CoV. 18 Various structures of nsp10-nsp16 from SARS-COV-2 have been recently deposited in Protein Data Bank (PDB) such as PDB IDs: 6W4H, 6W75, 6WJT, 6WKQ, 6WVN, 6WQ3 and 6WRZ. 28 These include the SARS-CoV-2 nsp10-nsp16 in complex with SAM (6W75), SAH (6WJT), sinefungin (6WKQ) and in complex with both RNA (N7-meGpppA) and SAM (6WVN) or RNA (N7-meGpppA) and SAH (6WQ3 and 6WRZ). 28 Along with previously available structures from SARS-CoV nsp10-nsp16 (PDB IDs: 2XYR, 2XYV, 2XYQ, 3R24) 18, 22 and MERS-CoV nsp16 (PDB ID: 5YN5), these structures provide vast amount of information on interaction of substrates with nsp16 and could be used in structure guided drug discovery (Fig. 2) .

Here we report the development of a cost-effective fluorescence polarization-based RNAdisplacement assay which is suitable for high-throughput screening of nsp10-nsp16 complex against large libraries of compounds to identify RNA competitive inhibitors of nsp16 methyltransferase activity. This assay is also a perfect tool for triaging a high number of potential inhibitors from screening by alternative methods for competing with RNA substrate and determining their mechanism of inhibition.

S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH) and sinefungin were purchased from Sigma-Aldrich. FAM labelled RNA (5' N7-meGpppACCCCC-FAM 3′) and biotinylated RNA (5' N7-MeGpppACCCCC-Biotin 3′) were purchased from bioSYNTHESIS (Levisville, Texas). The unlabelled Cap RNA, m7G(5´)ppp(5´)G (NEB, #S1404S) and m7G(5´)ppp(5´)A (NEB, #S1405S) also referred throughout the manuscript as N7-meGpppG and N7-meGpppA for consistency, respectively, and G(5′)ppp(5′)A RNA (GpppA) (NEB, # S1406S) and G(5′)ppp(5′)G RNA (GpppG) (NEB, # S1407S) are from New England Biolabs (NEB). NEB RNA reagents were gifts from Dr. Peter Stogios, University of Toronto. All RNA solutions were prepared by dissolving in nuclease free water, in the presence of RNAseOUT (Life Technologies) at a final concentration of 0.4 U/µL.

Expression and purification of nsp10 and nsp16, and nsp10-nsp16 complex preparation have been described in detail in Supplementary data (Supplementary Fig. 1, 2 and 3) . 

The Z′-factor was determined by incubating nsp10-nsp16 complex (0.5 µM) with 30 nM FAM-RNA in the presence or absence of 50 µM unlabeled RNA (N7-meGpppA) in a 384-well plate for 30 min at room temperature (168 wells each). Fluorescence polarization was measured as described above.

Prestwick Chemical Library was purchased from Prestwick Chemicals and was screened using optimized assay conditions (10 mM Tris buffer pH 7.5 containing 5 mM DTT, 0.01% Triton X-100, 0.01% BSA) at 50 µM compound concentration, with 0.5% DMSO concentration in 384-well black polypropylene PCR plates (Axygen, Tewksbury, MA, USA; cat. PCR-384-BK) with a final reaction volume of 20 µL for 30 min at room temperature. Data were analyzed using GraphPad Prism 7.04 as described above.

Binding of SAM, SAH, and sinefungin to nsp10-nsp16 (8:1) complex was tested by Nano ITC 

His-tagged nsp10 (residues A1-Q139) and nsp16 (S1 -N298) were expressed in E. coli separately and purified to homogeneity using Ni-NTA resin as described in the supplementary material and methods (Supplementary Fig.1) . Purified nsp10 and nsp16 proteins were mixed at a molar ratio of 8 to 1, respectively, to prepare stable and functional complex. The complex formation was evaluated by running a sample of expected complex through size exclusion chromatography which confirmed complex formation (Supplementary Fig. 2 ). In addition, the presence of intact nsp10 and nsp16 in the complex fractions were verified by mass spectrometry (Supplementary Fig. 3) .

To evaluate the functional integrity of the prepared complex, we tested the binding of the methyl donor SAM, product of the reaction SAH, and a common methyltransferase inhibitor sinefungin using ITC. Nsp10-nsp16 complex showed binding to SAM, SAH and sinefungin with Kd values of 3.4 ± 1.5 µΜ, 5.7 ± 1.9 µΜ, and 6.8 ± 2.0 µΜ, respectively, indicating the protein complex was formed and maintained the expected active site conformation (Fig. 3) .

We used a FAM-labelled RNA (5' N7-meGpppACCCCC-FAM 3′) to set up an RNA displacement assay. We first tested binding of this RNA to the nsp10-nsp16 complex. We observed significant fluorescence polarization (FP) signal and proceeded to optimize the assay conditions ( Supplementary Fig. 4) . Various buffer conditions such as 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), Bis-Tris Propane (BTP), Sodium phosphate (NaP), Tris(hydroxymethyl)aminomethane (Tris) and Potassium phosphate (KP) at 20 mM, pH 7.5 were tested and the FP signal was relatively higher in Tris and HEPES than other buffers ( Supplementary Fig. 4A ).

We selected to use 10 mM Tris for testing additives, which provided the highest signal ( Supplementary Fig. 4B ). The signal was unaffected up to 1% BSA, 10 mM of TCEP, KCl and MgCl2 (Supplementary Fig. 4C to 4F) . The pH profile showed pH 7.5 as optimum (Fig. 4A) . The signal was not significantly affected by increasing concentrations of DTT (Fig. 4B) , and NaCl ( Fig. 4C) , or EDTA (Fig. 4D ) up to 10 mM. Triton X-100 (Fig. 4E) and DMSO (Fig. 4F ) had no significant effect on signal up to 1% and 5%, respectively. DTT was selected to be used at 5 mM in assays to maintain a reducing environment. Addition of Triton X-100 at 0.01% is expected to help minimizing binding of fluorophores and proteins to polystyrene plates 29 and compound aggregate formation in screening 30 . BSA was also included at 0.01% to prevent non-specific interactions. Based on optimization results, the final assay buffer and screening conditions established consisted of 5 mM DTT, 0.01% Triton X-100, 0.01% BSA in 10 mM Tris buffer pH 7.5, and incubation time of 30 min.

Using the optimized assay conditions, nsp10-nsp16 complex showed concentration dependent binding to the FAM-RNA at 30 nM with an apparent Kd of 0.13 ± 0.002 µM and Bmax of 270 ± 5 mP (Fig. 5A) . For RNA-displacement assays, the protein complex concentration was kept at 80% of maximum signal (0.5 µM) to allow better competitive displacement. Unlabelled methylated RNA cap analogues, N7-meGpppG and N7-meGpppA, were used to compete off the FAM-RNA binding to nsp10-nsp16 complex. Both N7-meGpppG and N7-meGpppA displaced FAM-RNA with Kdisp values of 17 ± 3 µM and 20 ± 6 µM, respectively ( Fig. 5B and 5C) , while unlabelled unmethylated cap analogues GpppG (Fig. 5D) and GpppA (Fig. 5E) were unable to displace FAM-RNA from nsp10-nsp16 complex. C-terminally biotinylated 5′ N7-methylated GpppACCCCC 3′ also displaced the FAM-RNA with Kdisp of 4.3 µM (Supplementary Fig. 5) .

These observations further confirmed that the nsp10-nsp16 protein complex specifically recognizes its N7-me RNA substrate.

To determine whether the RNA-displacement assay at optimized conditions is amenable to highthroughput screening, the Z′-factor was determined by performing the assay in a 384-well format using FAM-RNA (5' N7-meGpppACCCCC-FAM 3′) in the presence (168 data points) and absence (168 data points) of 50 µM unlabelled RNA (N7-meGpppA). The calculated Z′-factor was 0.6, indicating the assay is suitable for screening for RNA competitive inhibitors (Fig. 5F ).

We further screened a collection of 1124 small molecules from the Prestwick Chemical Library, a collection of drugs and drug-like compounds. Screening of this library initially identified 15 compounds as potential antagonists of nsp10-nsp16-RNA interaction based on reduction of polarization signal (>50% reduction) compared to the control at 50 µM final compound concentration (Fig. 6) .

All 15 compounds were tested for any possible interference with the signal readout, and 12 compounds showed a significant effect and were eliminated. Three compounds showed dosedependent displacement with no signal interference. However, considering the high Hill slopes as a red flag, we further tested the binding of these 3 compounds to nsp10-nsp16 complex by ITC and none of the compounds was confirmed. The screening test run once again confirmed the suitability of the optimized RNA displacement assay for medium to high throughput screening of nsp10-nsp16 complex.

The COVID-19 pandemic has an unprecedented impact on the global economy and has already brought the health care services worldwide to a breaking point. So far, there are no approved vaccine or effective drugs for this disease. Even vaccines developed today may not be effective on future mutated variants. 31 This necessitates the development of therapeutics that could stop the replication of the SARS-CoV-2. Coronavirus caps its RNA to evade human immune system and preserve its RNA from degradation, which is essential for viral replication. 15, 32 RNA-capping is catalyzed by non-structural enzymes including nsp16 which is a SAM-dependent RNAmethyltransferase, and active when in complex with nsp10. 26 Methyltransferases have been shown to be druggable 33 with more than 20 potent, selective, and cell active small molecules (chemical probes) discovered for such enzymes in the last decade 33 . Typically, both SAM 34 and substrate binding sites of methyltransferases could be targeted for drug discovery. 33 One of the cost-effective ways of screening for RNA substrate competitive inhibitors is to label the RNA with fluorescein and detect its binding to the target RNA methyltransferase by monitoring the change in fluorescent polarization signal. 35 In this study, we have developed and optimized a fluorescence polarization (FP)-based RNA displacement assay in a 384-well format for nsp10-nsp16 complex which is suitable for screening to identify RNA-competitive inhibitors. This assay is also suitable for triaging RNA-competitive small molecules from a high number of hits that could be identified by other types of screening.

SAM has been reported to promote active MERS nsp10-nsp16 complex assembly and SAM/SAH balance regulating nsp16 activity. 26 The Kd values reported for SAM binding to SARS-CoV nsp10-nsp16 complex (Kd = 5.59 ± 1.15 µΜ) 22 are within the same range as we report for SARS-CoV-2 nsp10-nsp16 complex binding to SAM (Kd = 3.4 ± 1.5 µΜ). This indicates the highly conserved interaction of co-factor SAM with nsp10-nsp16 from these coronaviruses. The FAM labelled RNA substrate in this study (5' N7-meGpppACCCCC-FAM 3′) was designed based on the previous studies on SARS-CoV nsp10-nsp16 complex reporting recognition of cap-0 RNA (N7-meGpppA-RNA) as substrate but not N7-meGpppG-capped RNA. 22 In vitro, RNA substrate for SARS-CoV nsp10-nsp16 needs to be N7 guanine methylated with adenine (A) as the first nucleotide 23 . We Protein expression and purification DNA sequences encoding the full-length SARS-CoV-2 nsp10 (residues A4254-Q4392 / A1-Q139) and nsp16 (residues S6799-N7096 / S1-N298) were chemically synthesized according to the UniProtKB reference sequence P0DTD1. The DNA fragments were individually cloned into the pET28-MHL expression vector (GenBank: EF456735.1) adding a N-terminal purification tag (MHHHHHHSSGRENLYFQG).

Constructs were transformed into Escherichia coli BL21 (DE3) RIL, then the cells were cultured in LB Broth overnight at 37 °C. The next day, the overnight cultures were used to inoculate Terrific Broth supplemented with 50 µg/mL Kanamycin and 35 µg/mL chloramphenicol for further amplification at 37 °C using LEX system (https://www.thesgc.org/science/lex). Once the OD600 of the cultures reached 0.8-1.5, the temperature was lowered to 18 °C and the target proteins were overexpressed overnight by inducing cells with 1 mM IPTG (isopropyl-1-thio-Dgalactopyranoside). The cells were harvested the next day at 7000 rpm for 10 minutes at 4 °C (Beckman Coulter centrifuge).

Harvested cells from nsp10 and nsp16 cultures were re-suspended in binding buffer containing 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 5% Glycerol, 0.5 mM TCEP, 5 mM imidazole and 50 mM Tris-HCl pH 9.0, 500 mM NaCl, 5% Glycerol, 0.5 mM TCEP, 5 mM imidazole, respectively supplemented with 1X protease inhibitor cocktail (100X protease inhibitor stock in 70% ethanol containing 0.25 mg/mL Aprotinin, 0.25 mg/mL Leupeptin, 0.25 mg/mL Pepstatin A and 0.25 mg/mL E-64) or Roche complete EDTA-free protease inhibitor cocktail tablet. The cells were lysed chemically by rotating 30 min with CHAPS (final concentration of 0.5%) and 5 µL/L Benzonase Nuclease (in house) followed by sonication at frequency of 8.0 (10s on/7s off) for 5 min (Sonicator 3000, Misoni). The crude extract was clarified by high-speed centrifugation for 45 min at 16000 rpm at 4 °C (Beckman Coulter centrifuge).

The lysates were then separately loaded onto Ni-NTA affinity resin column (Qiagen) preequilibrated with the corresponding binding buffers. The column for nsp10 was washed with running wash buffer (binding buffer plus 30 mM imidazole). The column for nsp16 was once washed by wash buffer and 4 more times with binding buffer. Subsequently, the columns were eluted with the corresponding binding buffers containing 250 mM imidazole (Fig. S1) . Then, the nsp16 and nsp10 proteins were mixed at 1:8 molar ratio and the mixture was dialyzed in final buffer containing 50 mM Tris-HCl pH 8.0, 200 mM NaCl, 5% glycerol, 0.5 mM TCEP for a total of 60 minutes while spinning at 4 °C. Then, the complex was flash frozen and stored at -80 °C.

We evaluated nsp10-nsp16 complex formation by Size-Exclusion Chromatography (SEC). Initially, a SEC standard (Bio-Rad) was loaded onto Superdex 200 16/600 column after equilibration with 50 mM Tris-HCl pH 8.0 buffer containing 200 mM NaCl, 5% glycerol, 0.5 mM TCEP. The standard peaks were used to plot the calibration curve. Then, the protein sample was loaded onto the column and the molecular weight of the protein fractions were calculated according to the calibration curve (Fig. S2) . The molecular weight of the nsp10 and nsp16 was confirmed by running 10 μg of protein complex on mass spectrometer (Agilent Technologies, 6545 Q-TOF LC/MS) (Fig. S3) . 

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

The proximal origin of SARS-CoV-2

Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2012)

Coronaviridae Study Group of the International Committee on Taxonomy of, V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Hosts and Sources of Endemic Human Coronaviruses

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Coronaviruses: structure and genome expression

Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

A new coronavirus associated with human respiratory disease in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Continuous and Discontinuous RNA Synthesis in Coronaviruses

A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping

Conventional and unconventional mechanisms for capping viral mRNA

The viral RNA capping machinery as a target for antiviral drugs

Crystal structure and functional analysis of the SARScoronavirus RNA cap 2'-O-methyltransferase nsp10/nsp16 complex

Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes

Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase

Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase

Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex

In vitro reconstitution of SARS-coronavirus mRNA cap methylation

Structure-function analysis of severe acute respiratory syndrome coronavirus RNA cap guanine-N7-methyltransferase

Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity

Binding of the Methyl Donor S-Adenosyl-l-Methionine to Middle East Respiratory Syndrome Coronavirus 2'-O-Methyltransferase nsp16 Promotes Recruitment of the Allosteric Activator nsp10

Molecular mapping of the RNA Cap 2'-O-methyltransferase activation interface between severe acute respiratory syndrome coronavirus nsp10 and nsp16

High-resolution structures of the SARS-CoV-2 2'-O-methyltransferase reveal strategies for structure-based inhibitor design

Inhibition of Protein-Protein Interactions: Cell-Based Assays

Bethesda (MD)

A specific mechanism of nonspecific inhibition

The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses

Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5

A chemical biology toolbox to study protein methyltransferases and epigenetic signaling

Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor

A Suite of Biochemical Assays for Screening RNA Methyltransferase BCDIN3D